Spots Global Cancer Trial Database for Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
Official Title: An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS)
Study ID: NCT00017550
Conditions
Interventions
Study Description
Brief Summary: RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome. PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.
Detailed Description: OBJECTIVES: * Compare the clinical response rate of patients with early myelodysplastic syndrome treated with rabbit anti-thymocyte globulin vs standard supportive care. * Evaluate the safety of anti-thymocyte globulin in these patients. * Compare the time to and duration of clinical response, rates of partial response and therapy failure, and rate of disease progression in patients treated with these regimens. * Compare the ECOG performance score, number of transfusions and/or growth factor use, and maximum time between transfusions in patients treated with these regimens. * Compare the infection risk, use of medical resources, and quality of clinical response in patients treated with these regimens. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to myelodysplastic syndrome (MDS) subtype (refractory anemia (RA) vs RA with excess blasts or hypocellular MDS). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive rabbit anti-thymocyte globulin (ATG) IV over at least 8-12 hours on days 1-4. * Arm II: Patients receive standard supportive therapy for 6 months. At the end of 6 months, patients may receive ATG as in arm I. Patients are followed for 6 months. PROJECTED ACCRUAL: A total of 72 patients (48 in arm I and 24 in arm II) will be accrued within a minimum of 6 months.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Washington Cancer Institute, Washington, District of Columbia, United States
University of Florida Health Science Center, Gainesville, Florida, United States
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Veterans Affairs Medical Center - Tampa (Haley), Tampa, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Rush Cancer Institute, Chicago, Illinois, United States
Indiana Blood and Marrow Transplant, Beech Grove, Indiana, United States
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Tulane University School of Medicine, New Orleans, Louisiana, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States
Saint Louis University Cancer Center, Saint Louis, Missouri, United States
Siteman Cancer Center, Saint Louis, Missouri, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
Mount Sinai Medical Center, NY, New York, New York, United States
James P. Wilmot Cancer Center, Rochester, New York, United States
New York Medical College, Valhalla, New York, United States
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Texas Oncology P.A., Dallas, Texas, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Foothills Hospital, Calgary, Alberta, Canada
Department of Medicine, Vancouver, British Columbia, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
Contact Details
Name: Elizabeth C. Squiers, MD
Affiliation: Sangstat Medical Corporation
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
